Skip to main content
OpenTrials
Completed

NCT Number: NCT03884309

Evaluation of Infants Fed an Extensively Hydrolyzed Infant Formula

This is a single group, non-randomized, multicenter study to assess the effects of a hypoallergenic casein hydrolysate powdered infant formula on gastrointestinal (GI) tolerance, growth and compliance in an intended use infant population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

Up to 60 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Paramount Research Solutions, College Park, Georgia, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is presently consuming an extensively hydrolyzed infant formula (EHF) for persistent feeding intolerance symptoms, symptoms of suspected food protein (milk and/or soy) sensitivity, or other conditions where EHF is deemed an appropriate feeding.
  • Parent(s) of infants confirm their intention not to administer prescription medications, over the counter medications, home remedies, prebiotics, probiotics, herbal preparations or rehydration fluids that might affect GI tolerance.
  • Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study.
  • Parent(s) confirm their intention not to administer vitamins, minerals (with the exception of Vitamin D supplements), solid foods or juices to their infant from enrollment through the duration of the study.
  • Participant's parent(s) or a legally authorized representative (LAR) has voluntarily signed and dated an informed consent form (ICF) approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.

Exclusion criteria

  • An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on growth, and/or development.
  • Participant is receiving oral or inhaled steroids.
  • Participant participates in another study that has not been approved as a concomitant study.
  • Participant has an allergy or intolerance to any ingredient in the study product.
  • Participant has been treated with antibiotics or other medications that in the opinion of the PI may affect growth, GI tolerance and/or development, within 2 weeks prior to enrollment.

Treatment and study plan

Experimental Hydrolyzed Protein Infant Formula

Other

fed ad libitum

Primary outcomes

  1. Weight for Age

    Time frame: Study Day 1 to Study Day 60

    Change in weight for age z-score

Secondary outcomes

  1. Gastrointestinal Tolerance

    Time frame: Study Day 1 to Study Day 60

    Parent completed diary questions

  2. Length

    Time frame: Study Day 1 to Study Day 60

    Gain measured in cm

  3. Head Circumference

    Time frame: Study Day 1 to Study Day 60

    Gain measured in cm

Sponsors and collaborators

Lead sponsor

Abbott Nutrition

Industry

Registry information

Official study title

Tolerance, Compliance and Growth of Infants Fed an Extensively Hydrolyzed Infant Formula With Added Human Milk Oligosaccharides

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Mar 21, 2019
Registry last updated
Feb 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.